138458 - Pre-exposure Prophylaxis in General Practice
- : Online
This Clinical Audit is designed to assist GPs to identify and appropriately manage patients at risk of HIV using the Pre-exposure Proplyaxix (PrEP) combination anti-retroviral medication that was recently listed on the PBS. This audit is an optional activity for GPs participating in 2018 GP Update face to face or online course.Relevance to General Practice
Prescribing this drug aligns with the government's strategy to eliminate HIV transmission by 2020.
Daily use of coformulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines.
Excerpt from ASHM Journal of Virus Eradication: http://viruseradication.com/journal-details/Australasian_Society_for_HIV,_Viral_Hepatitis_and_Sexual_Healt h_Medicine_HIV_pre-exposure_prophylaxis:_clinical_guidelines._Update_April_ 2018/